Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1:EVIDoa2200008.

Article  PubMed  Google Scholar 

Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L-P, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes. J Clin Oncol. 2023;41:2827–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015;29:1496–501.

Article  CAS  PubMed  Google Scholar 

Kröger N, Sockel K, Wolschke C, Bethge W, Schlenk RF, Wolf D, et al. Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study). J Clin Oncol. 2021;39:3318–27.

Nakamura R, Saber W, Martens MJ, Ramirez A, Scott B, Oran B, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39:3328–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duncavage EJ, Jacoby MA, Chang GS, Miller CA, Edwin N, Shao J, et al. Mutation clearance after transplantation for myelodysplastic syndrome. N Engl J Med. 2018;379:1028–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tobiasson M, Pandzic T, Illman J, Nilsson L, Weström S, Ejerblad E, et al. Patient-specific measurable residual disease markers predict outcome in patients with myelodysplastic syndrome and related diseases after hematopoietic stem-cell transplantation. J Clin Oncol. 2024:42:1378–90.

Schulz E, Aplan PD, Freeman SD, Pavletic SZ. Moving toward a conceptualization of measurable residual disease in myelodysplastic syndromes. Blood Adv. 2023;7:4381–94.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Festuccia M, Deeg HJ, Gooley TA, Baker K, Wood BL, Fang M, et al. Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome. Biol Blood Marrow Transpl. 2016;22:1227–33.

Article  Google Scholar 

Hong S, Rybicki L, Gurnari C, Pagliuca S, Zhang A, Thomas D, et al. Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transpl. 2022;57:1615–9.

Article  Google Scholar 

Hou C, Zhou L, Yang M, Jiang S, Shen H, Zhu M, et al. The prognostic value of early detection of minimal residual disease as defined by flow cytometry and gene mutation clearance for myelodysplastic syndrome patients after myeloablative allogeneic hematopoietic stem-cell transplantation. Front Oncol. 2021;11:700234.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee J-M, Kim Y-J, Park S-S, Han E, Kim M, Kim Y. Simultaneous monitoring of mutation and chimerism using next-generation sequencing in myelodysplastic syndrome. J Clin Med. 2019;8:2077.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16:2115–21.

Article  CAS  PubMed  Google Scholar 

Woo J, Howard NP, Storer BE, Fang M, Yeung CC, Scott BL, et al. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes. Haematologica. 2017;102:e216–8.

Article  PubMed  PubMed Central  Google Scholar 

Heuser M, Heida B, Büttner K, Wienecke CP, Teich K, Funke C, et al. Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Adv. 2021;5:2294–304.

Article  CAS  PubMed  PubMed Central  Google Scholar